Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2NET 1Genitourinary 1Endocrine 1

Conditions

Neuroendocrine Tumors 26Sarcoma 4Carcinoma, Neuroendocrine 4Prostatic Neoplasms 3Pheochromocytoma 3Paraganglioma 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 3Breast Neoplasms 3Adenoma, Islet Cell 3Thyroid Neoplasms 2Stomach Neoplasms 2Neoplasms by Site 2Neoplasms by Histologic Type 2Meningioma 2Melanoma 2Liver Neoplasms 2Head and Neck Neoplasms 2Gastrointestinal Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Digestive System Neoplasms 2Colonic Neoplasms 2Colonic Diseases 2Carcinoma, Renal Cell 2Carcinoid Tumor 2Adenocarcinoma 2

Interventions

pembrolizumab 1PT-100 dipeptide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × NET × 30 days × Clear all
NCT03910660 2026-05-15

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

BioXcel Therapeutics Inc

Phase 1/2 Completed
98 enrolled
EndocrineGenitourinaryNET

Prostatic Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡